NovoCure (NVCR) – Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for NovoCure (NASDAQ: NVCR):

• 8/8/2026 – NovoCure was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/24/2026 – NovoCure was given a new $32.00 price target by HC Wainwright.
• 7/24/2026 – NovoCure was upgraded by Zacks Research from “strong sell” to “hold”.
• 7/24/2026 – NovoCure had its price target raised by Wedbush from $18.00 to $20.00. They now have a “neutral” rating on the stock.
• 7/23/2026 – NovoCure had its price target raised by HC Wainwright from $46.00 to $52.00. They now have a “buy” rating on the stock.
• 7/14/2026 – NovoCure was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/13/2026 – NovoCure is now covered by JPMorgan Chase & Co.. They set a “neutral” rating and a $17.00 price target on the stock.
• 6/18/2026 – NovoCure had its “buy” rating reaffirmed by HC Wainwright. They now have a $46.00 price target on the stock, down from $48.00.

Insiders Place Their Bets

In other news, CEO Frank X. Leonard sold 34,273 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $17.93, for a total transaction of $614,514.89. Following the completion of the transaction, the chief executive officer owned 459,520 shares in the company, valued at $8,239,193.60. This trade represents a 6.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Allyson J. Ocean sold 2,945 shares of NovoCure stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $15.77, for a total value of $46,442.65. Following the completion of the sale, the director directly owned 11,324 shares in the company, valued at $178,579.48. This trade represents a 20.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 51,943 shares of company stock worth $893,171. 6.55% of the stock is owned by corporate insiders.

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.